億帆醫藥(002019.SZ):收到原料藥上市申請批准通知書
格隆匯3月14日丨億帆醫藥(002019.SZ)公佈,公司全資子公司宿州億帆藥業有限公司於2023年3月13日收到國家藥品監督管理局核准簽發的重酒石酸去甲腎上腺素《化學原料藥上市申請批准通知書》。
本產品為重酒石酸去甲腎上腺素注射液的原料藥,重酒石酸去甲腎上腺素注射液可用於某些急性低血壓狀態(例如嗜鉻細胞切除術、交感神經切除術、脊髓灰質炎、脊髓麻醉、心肌梗死、敗血症、輸血和藥物反應)的血壓控制。作為心臟驟停和嚴重低血壓的輔助治療手段。對血容量不足導致的休克,本品作為急救時補充血容量的輔助治療,以使血壓回升,暫時維持腦與冠狀動脈灌注,直到補充血容量治療發生作用;也可用於心跳驟停復甦後血壓維持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.